These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35770744)

  • 1. Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer (nmCRPC) patients.
    Nishimura K; Shiota M; Eto M; Satoh T; Stroupe A; Seo C; Uzumcu A; Ledesma DA
    Cancer Med; 2023 Jan; 12(2):1762-1778. PubMed ID: 35770744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.
    Holmstrom S; Naidoo S; Turnbull J; Hawryluk E; Paty J; Morlock R
    Patient; 2019 Feb; 12(1):57-67. PubMed ID: 30519830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings.
    Tomaszewski EL; Moise P; Krupnick RN; Downing J; Meyer M; Naidoo S; Holmstrom S
    Patient; 2017 Oct; 10(5):567-578. PubMed ID: 28285412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
    Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
    Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
    Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
    Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Nonmetastatic Castration-resistant Prostate Cancer.
    Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
    Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
    Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
    Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
    Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
    Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
    Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
    Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the patient experience of chronic kidney disease stages 2-3b: a qualitative interview study with Kidney Disease Quality of Life (KDQOL-36) debrief.
    Rydén A; Nolan S; Maher J; Meyers O; Kündig A; Bjursell M
    BMC Nephrol; 2022 Jun; 23(1):201. PubMed ID: 35641914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
    Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
    Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
    Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
    Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
    Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan.
    Mori A; Hashimoto K; Koroki Y; Wu DB; Masumori N
    Curr Med Res Opin; 2019 Oct; 35(10):1745-1750. PubMed ID: 31084438
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Health Economics of Metastatic Hormone-Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer-A Systematic Literature Review with Application to the Canadian Context.
    Yanev I; Gatete J; Aprikian AG; Guertin JR; Dragomir A
    Curr Oncol; 2022 May; 29(5):3393-3424. PubMed ID: 35621665
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.
    Clark MJ; Harris N; Griebsch I; Kaschinski D; Copley-Merriman C
    Health Qual Life Outcomes; 2014 Jul; 12():104. PubMed ID: 24989428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.